URGN vs. ADPT, GYRE, PSTX, OCS, NUVB, AVXL, ABCL, CVAC, AVBP, and COGT
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), AbCellera Biologics (ABCL), CureVac (CVAC), ArriVent BioPharma (AVBP), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.
UroGen Pharma vs.
UroGen Pharma (NASDAQ:URGN) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.
UroGen Pharma received 271 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 73.94% of users gave UroGen Pharma an outperform vote while only 57.58% of users gave Adaptive Biotechnologies an outperform vote.
91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.1% of UroGen Pharma shares are owned by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Adaptive Biotechnologies has a net margin of -110.13% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.
UroGen Pharma currently has a consensus target price of $43.70, indicating a potential upside of 325.51%. Adaptive Biotechnologies has a consensus target price of $6.75, indicating a potential downside of 0.88%. Given UroGen Pharma's stronger consensus rating and higher probable upside, research analysts plainly believe UroGen Pharma is more favorable than Adaptive Biotechnologies.
In the previous week, UroGen Pharma and UroGen Pharma both had 4 articles in the media. UroGen Pharma's average media sentiment score of 0.74 beat Adaptive Biotechnologies' score of 0.54 indicating that UroGen Pharma is being referred to more favorably in the media.
UroGen Pharma has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.
UroGen Pharma has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
UroGen Pharma beats Adaptive Biotechnologies on 10 of the 18 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:URGN) was last updated on 1/20/2025 by MarketBeat.com Staff
